HIGHLIGHTS
- who: Franco Locatelli from the IRCCS Ospedale Pediatrico Bambino Gesu00f9, Catholic University of the Sacred Heart, Rome, Italy Amgen Research (Munich) GmbH, Munich, MBBM Foundation have published the research work: Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL, in the Journal: (JOURNAL) of 26/08/2022
SUMMARY
Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, et_al Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.